Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venlafaxine versus placebo in Japanese adolescents with depressive disorders
2024-000604-29Phase 3
- Sponsor
- Viatris
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) and persistent depressive disorder (PDD) comparing Venlafaxine with Placebo (2 arms). Primary endpoint: Change from baseline in Children Depression Rating Scale-Revised score at Week 8.
02
Drugs
venlafaxine
03
Conditions
major depressive disorder (MDD)persistent depressive disorder (PDD)
Beyond the preview
Go deeper on 2024-000604-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-000604-29.